Cardiol Therapeutics (CRDL) Assets Average (2021 - 2026)

Cardiol Therapeutics has reported Assets Average for 6 years, with the latest figure at $19.9 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 1.75% year-over-year to $19.9 million; the trailing twelve-month figure through Mar 2026 stood at $19.9 million (down 1.75% YoY), and the FY2025 full-year result was $19.9 million, down 20.13% from the prior year.
• Assets Average for Q1 2026 stood at $19.9 million, up from $13.2 million in the prior quarter.
• The five-year high for Assets Average was $66.2 million in Q1 2022, with the low at $11.9 million in Q3 2025.
• Historically, Assets Average has averaged $31.5 million across 5 years, with a median of $25.0 million in 2024.
• Annual changes were most pronounced in 2022 — Assets Average surged 100.82% — and 2024, when it plunged 52.28%.
• Cardiol Therapeutics' Assets Average stood at $49.1 million in 2022, then plunged by 39.79% to $29.5 million in 2023, then plunged by 39.65% to $17.8 million in 2024, then fell by 26.1% to $13.2 million in 2025, then soared by 51.22% to $19.9 million in 2026.
• The last three Assets Average figures came in at $19.9 million (Q1 2026), $13.2 million (Q4 2025), and $11.9 million (Q3 2025), per Business Quant data.